Allison Chang
@aebchang
Neuroscientist ➡️ Thoracic Medical Oncologist specializing in #earlydetection #AI #ML @mghcancercenter @harvard Cat mom. Human mom. Wife. Opinions mine.
Outstanding video explaining Sybil, a powerful new AI model built by my mentor @LeciaSequist, @BarzilayRegina, @F_Fintelmann_MD et al that will change how we think about predicting future illness--starting with #lungcancer! #LCSM @MGHCancerCenter @MassGeneralNews @MGHThoracicOnc
As lung cancer rates rise in nonsmokers, a troubling trend for the #1 deadliest cancer, we hope more hospitals will adopt tools like Sybil, an AI model built by #JClinic & @MassGenBrigham researchers that predicts lung cancer risk up to 6 years in advance. youtu.be/xGSiP8i4VbU
Thank you so much for having me! It is always such a privilege to join @AmLungCSI. A truly inspirational group.
This weekend, we had our July 2025 Intercollegiate Meeting with our incredible ALCSI chapter leaders! We also had the pleasure of being joined by Dr. Allison Chang (@aebchang), who shared about the amazing work she is doing with the LEGACY study to quantify cancer risk in…
👇 In honor of my 1st day as an attending, bringing back my favorite snapshot of life as a mom + physician trainee. 😅🫣 Jokes aside, THANK YOU to the village who got me through training with 2 kids: @harvardmed @BrighamMedRes, @danafarber @MGHCancerCenter, and my family. ❤️🙏
When you’re the only female CCU resident *and* the only team member to respond to your program’s request for casual photos for a COVID-era patient face sheet. 😅😅😅 #classic #fivedoctorsandamom #womeninmedicine
🚨‼️ Time to update @USPSTF guidelines! #PotterCriteria #LCSM
Check out this exciting new study led by @MattSmeltzer @ROsarogiagbon in @JAMANetworkOpen!! Changing the USPSTF lung screening criteria from a 20-pack-year cutoff to a 20-year duration cutoff (Potter Criteria) greatly increases access to screening while maintaining screening…
NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w led to MPR rate 25%, osi + chemo MPR 26%, placebo + chemo MPR 2%. EFS rates high but most pts received adjuvant osi. ascopubs.org/doi/10.1200/JC…
💫 Rising star Dr. Catherine Meador with a clear and nuanced discussion of multiple practice changing talks in #SCLC. #ASCO25 @MassGeneralNews @MGHCancerCenter @MGHThoracicOnc
Major #ASCO2025 take home re: #MCEDs nicely laid out by @max_diehn: We might have have reached the limit of detection of methylation-based MCEDs, and it’s fairly low for early stage #cancer. The signal is there (see tumor-informed assays), but we need to innovate to capture it.
Potentially practice changing if this holds up. Need additional studies to see if these findings generalize to other practice settings and to gain insights into mechanism of action.
This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
Powerful talk by #lungcancerscreening visionary Nasser Hanna @hannawants2ELCN with a call to action and a blueprint for improving #lungcancer survival through early detection in your community. 🚨 💪 #lcsm
One of the more exciting #lungcancer talks at #ASCO2025 so far.
Striking activity with ABBV-706 SEZ6 ADC in high grade neuroendocrine cancer (NECs) where active therapies are urgently needed. Thank you to the patients and their families. @alissajcooper #LCSM
Thank you @ASCO for the opportunity to present our work. Incredibly grateful to @KimmieNgMD and Chen Yuan for their mentorship @DanaFarber
.@sarakcharMD presents intriguing findings on how diet impacts survival in stage III colon cancer patients. The study examines the link between dietary inflammation and outcomes, offering insights into nutrition's role in cancer care. #ASCO25
Thank you @WSJ for featuring our work! Healthy diet and physical activity are essential parts of colon cancer care and survivorship. Looking forward to presenting the results of our study examining inflammatory diet and colon cancer survival at #ASCO25 today at 4:30 pm in Hall B1
When facing down a cancer diagnosis, patients often ask what can help their odds. Doctors say that going back to basics could make a difference. on.wsj.com/4mYFRt5
Dr. @HelenaYu923 at #ASCO25 with results from REZILIENT1 of zipalertinib in #EGFR exon 20 NSCLC. RR 35% with efficacy after other exon 20 directed therapy like amivantamab. 39% paronychia but none grade 3.
Tough news on HER3-DXd. But negative trials don't always mean failed drugs. As a patient and advocate, I understand why (toxicities, lack of OS - they matter). But, I also find myself asking, why DID it work for the people it helped? What about trial design? Prior treatment(s)?…
NEWS FROM INDUSTRY: Source MERCK Update HERTHENA-Lung02 🫁 Daiichi Sankyo and Merck have voluntarily withdrawn their Biologics License Application seeking accelerated approval for patritumab deruxtecan (HER3-DXd) in the U.S. 🇺🇸for EGFR-mutated 🧬advanced non-small cell…
When your colleagues are also some of your favorite people. ❤️
Nothing like connecting with your co-fellows halfway across the country @DanaFarber @MGHCancerCenter
Smoking wasn’t only glamorous, it was endorsed by doctors.
Our study in JAMA found that most people eligible for #lungcancerscreening (LCS) are already getting screened for breast & colon cancers. LCS eligible adults ARE receptive to cancer screening. They are NOT “hard to reach,” they are “hardly reached.”
Such an honor to speak @ #EmTechCaribbean @techreview about the development/deployment of #AI/#ML models in healthcare. My tl;dr—We are now more limited by scarcity of quality data than by computational power. We must invest in building large, accurate, representative datasets.
Lung ca screening uptake is already low due to multilevel barriers. This type of misleading rhetoric isn’t helpful. The purpose of ca screening is to ⬇️ ca-specific mortality by detecting ca at early stage when more amenable to treatment, & in case of lung adenoCA, potential cure
Lung cancer screening doesn't actually improve all cause mortality. Long-Term follow-up of nlst is negative as is Nelson. This grant should have been terminated for different reasons. The media doesn't appreciate how bad the NIH funding system is.